Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantTR
T. Rowe Price Investment Management
Activity from announced rounds
Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.1B 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionOllin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedCellares
Cellares manufactures cell therapies for drug developers using automated production and quality-control systems deployed through its Smart Factory network.
$257MSeries D
Role not disclosedMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosed